Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.

Author: HuBei, HuYu, LiuJing-di, SunChun-Yan, TangLiang, WangQing-Yun, WuYing-Ying

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic literature review assessed the efficacy and safety of panobinostat for patients with relapsed or/and refractory multiple myeloma (MM). The study found that panobinostat combined with other agents had an overall response rate of 0.45 and was well tolerated.
Paper Details　
Original Abstract of the Article :
During the past decades, many novel agents have improved response and survival of patients with multiple myeloma. Nevertheless, it remains challenging when they suffer relapsing. Thus, novel therapeutic agents are needed. We aimed to assess the efficacy and safety of a novel agent panobinostat for p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895230/

データ提供：米国国立医学図書館（NLM）

Panobinostat: A New Weapon in the Fight Against Multiple Myeloma

The fight against multiple myeloma, a complex and often challenging cancer, is a continuous race for new and effective treatments. This comprehensive meta-analysis, published in [Journal name], examines the efficacy and safety of panobinostat, a novel agent, for patients with relapsed or refractory multiple myeloma. The researchers reviewed a total of 11 clinical trials involving 700 patients treated with panobinostat.

Panobinostat Shows Promise, but More Research Needed

The meta-analysis revealed a pooled overall response rate (ORR) of 0.45 for panobinostat combined with other drugs, indicating a potential benefit for patients. However, the study also highlighted the occurrence of common adverse effects, including thrombocytopenia, neutropenia, and diarrhea. While these findings are encouraging, further research is needed to understand the long-term efficacy and safety profile of panobinostat in patients with multiple myeloma.

Navigating the Shifting Sands of Cancer Treatment

The treatment of multiple myeloma is a complex and often unpredictable journey. This study, like a map through a shifting desert landscape, provides valuable information about a new therapeutic agent. While panobinostat shows promise, further research is needed to optimize its use and minimize potential side effects. As with any journey, it's essential to be prepared and to have a clear understanding of the risks and benefits before embarking on this treatment path.

Dr.Camel's Conclusion

The fight against multiple myeloma is a journey through a desert of uncertainties, but this meta-analysis offers a promising oasis. Panobinostat, a new drug, shows potential in battling this disease, but further research is necessary to chart the safest and most effective course. It's a journey that requires careful navigation and a commitment to continuous exploration.
Date :
  1. Date Completed 2018-04-16
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27270478

DOI: Digital Object Identifier

PMC4895230

Related Literature

Article Analysis
・Side Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.